

24th November, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

Dear Sir,

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

## Sub.: Intimation regarding issue of Commercial Papers

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has issued Commercial Paper ("CPs") for an amount of Rs. 300 Crores (Rupees Three Hundred Crores Only) on 24<sup>th</sup> November, 2017. Details of the same are as follows:

Issue size	Rs. 300 Crores
Listing of Commercial Papers	CPs are not proposed to be listed
Tenure of the instrument	180 days
Date of Allotment	24 <sup>th</sup> November, 2017
Date of Maturity	23 <sup>rd</sup> May, 2018
Coupon/ Interest offered	6.85% per annum
Schedule of payment of Interest	Payment on maturity i.e. 23 <sup>rd</sup> May, 2018
Schedule of payment of Principal amount	Payment on maturity i.e. 23 <sup>rd</sup> May, 2018
Charge / Security	Unsecured
Special right / interest / privileges attached	No special rights attached to CPs
Delay in payment of interest / principal amount for a period	Not Applicable
of more than three months from the due date or default in	
payment of interest / principal	
Details of any letter or comments regarding payment / non	Not Applicable
payment of interest, principal on due dates, or any other	
matter concerning the security and / or the assets along	
with its comments thereon, if any.	





ICRA Limited has granted rating of A1+ for issuance of Commercial papers by the Company.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY